Myoclonic Seizure drugs in development by stages, target, MoA, RoA, molecule type and key players, 2023

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myoclonic Seizure and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Myoclonic Seizure by eight companies/universities/institutes. The top development phase for Myoclonic Seizure is preclinical with five drugs in that stage. The Myoclonic Seizure pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Myoclonic Seizure pipeline products market are: Ionis Pharmaceuticals, Taysha Gene Therapies and ANLBio.

The key targets in the Myoclonic Seizure pipeline products market include Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20), Potassium Voltage Gated Channel Subfamily C Member 2 (Voltage Gated Potassium Channel Kv3.2 or KCNC2), and Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1).

The key mechanisms of action in the Myoclonic Seizure pipeline product include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31) Activator with one drug in Preclinical. The Myoclonic Seizure pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Myoclonic Seizure pipeline products market including Small Molecule, and Gene Therapy.

Myoclonic Seizure overview

Myoclonic seizures cause a quick, uncontrollable muscle movement with no change in level of awareness or consciousness. They are characterized by brief, jerking spasms of a muscle or a group of related muscles, but can sometimes affect wider areas of body.

For a complete picture of Myoclonic Seizure’s pipeline drug market, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.